Cash Flow Statement
Growth Metrics

Biolife Solutions (BLFS) Asset Writedowns and Impairment (2016 - 2023)

Biolife Solutions (BLFS) reported Asset Writedowns and Impairment of $8.3 million for Q3 2023, up 111.89% on a QoQ basis from -$69.9 million in Q4 2022.

Biolife Solutions (BLFS) has 4 years of Asset Writedowns and Impairment data on file, last reported at $8.3 million in Q3 2023.

  • Quarterly Asset Writedowns and Impairment changed N/A year-over-year to $8.3 million in Q3 2023, while the trailing twelve-month figure through Dec 2024 was -$61.6 million (changed N/A YoY) and the FY2023 annual result came in at $9.7 million, changed N/A from the prior year.
  • Asset Writedowns and Impairment improved to $8.3 million in Q3 2023 per BLFS's latest filing, from -$69.9 million in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $69.9 million in Q2 2022 and bottomed at -$69.9 million in Q4 2022.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Intuitive Surgical 156.17 Bn 151.78 Bn 1.83 Bn
2 Becton Dickinson 41.51 Bn 40.49 Bn 2.15 Bn
3 Resmed 30.43 Bn 28.77 Bn 890.98 Mn
4 West Pharmaceutical Services 22.78 Bn 22.26 Bn 296.40 Mn
5 Solventum 13.39 Bn 13.39 Bn 1.10 Bn
6 Cooper Companies 12.33 Bn 12.20 Bn 695.20 Mn
7 Align Technology 11.65 Bn 10.59 Bn 736.59 Mn
8 Baxter International 9.81 Bn 7.77 Bn 891.00 Mn
9 Aptargroup 7.39 Bn 7.19 Bn 351.91 Mn
10 Biolife Solutions 1.20 Bn 1.12 Bn 17.50 Mn

Historic Data

Download Data 🔒
DateValue
Sep 30, 2023 8.31 Mn
Sep 30, 2023 8.31 Mn
Dec 31, 2022 -69.90 Mn
Dec 31, 2022 -69.90 Mn
Jun 30, 2022 69.90 Mn
Jun 30, 2022 69.90 Mn
Dec 31, 2017 336.00
Dec 31, 2017 336.00
Sep 30, 2017 67,664.00
Sep 30, 2017 67,664.00
Jun 30, 2016 86,736.00
Jun 30, 2016 86,736.00